Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: results from a prespecified subgroup analysis of the CASSINI study
Authors
Vadhan-Raj, SMcNamara, Mairead G
Venerito, M
Riess, H
O'Reilly, EM
Overman, MJ
Zhou, X
Vijapurkar, U
Kaul, S
Wildgoose, P
Khorana, AA
Affiliation
The University of Texas MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Section of Cytokines and Supportive Oncology, Houston, TXIssue Date
2019
Metadata
Show full item recordCitation
Vadhan-Raj S, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman MJ, et al. Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: results from a prespecified subgroup analysis of the CASSINI study. J Clin Oncol. 2019;37(15_suppl):4016-.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.15_suppl.4016Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4016Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.15_suppl.4016